Latanoprost is a prostaglandin F2-alpha analog and the most widely prescribed first-line medication for open-angle glaucoma and ocular hypertension. It reduces intraocular pressure (IOP) by 25-35% from baseline with once-daily dosing, making it the most effective single-agent IOP-lowering class. It has a favorable systemic safety profile since it is administered topically with minimal systemic absorption.
Iris darkening (irreversible increased brown pigmentation)
Eyelash growth (longer, thicker, darker lashes)
Known hypersensitivity to latanoprost or benzalkonium chloride (preservative)1,2
Active intraocular inflammation (uveitis, iritis)2,6
The bottom line
Evidence rating strong. Most-documented uses: most effective single-agent iop reduction (25-35%), once-daily evening dosing for convenience, minimal systemic side effects. 10 sources indexed (2014–2024), with 1 interaction record on file.
The science
How it works, mechanistically.
Core mechanism
As a prodrug, latanoprost is hydrolyzed by corneal esterases to its biologically active acid form. It then binds to prostaglandin FP receptors in the ciliary muscle, triggering remodeling of the extracellular matrix and widening of intermuscular spaces. This increases uveoscleral (unconventional) outflow of aqueous humor by 50-80%, effectively reducing intraocular pressure. It may also slightly increase trabecular outflow.1,2
Class
Prostaglandin Analog / Ophthalmologic
Dosing
Dosing & protocol.
Common range
One drop (0.005%) in affected eye(s) once daily in the evening (as prescribed by your physician)
Recommended form
Ophthalmic solution (0.005%); preservative-free formulations available
Topical ophthalmic application; absorbed through cornea where it is activated by esterases. Apply nasolacrimal occlusion (press on inner corner of eye) for 1-2 minutes after instillation to minimize systemic absorption. Must be refrigerated before opening (room temperature OK for 6 weeks after).1
Safety
Full safety detail.
Side effects
Conjunctival hyperemia (eye redness, most common)
Iris darkening (irreversible increased brown pigmentation)
Eyelash growth (longer, thicker, darker lashes)
Periorbital skin darkening
Ocular irritation and foreign body sensation
Prostaglandin-associated periorbitopathy (deepening of upper eyelid sulcus with chronic use)
Contraindications
Known hypersensitivity to latanoprost or benzalkonium chloride (preservative)1,2
Active intraocular inflammation (uveitis, iritis)2,6
Risk factors for cystoid macular edema (aphakia, pseudophakia with torn posterior capsule)
Contact lens wearers should remove lenses before instillation (wait 15 minutes before reinserting)
THC-dominant cannabis can temporarily lower intraocular pressure, but the effect is short-lived and is not a reliable substitute for latanoprost. Using cannabis around eye-pressure checks can also make pressure look better than it is during the rest of the day. This matters because glaucoma progression is often silent until vision loss is advanced.
Recommendation: Do not replace or skip latanoprost because cannabis seems to lower eye pressure. Tell your eye clinician if you use THC-dominant cannabis, especially before pressure checks or visual-field testing. Keep latanoprost dosing consistent and seek ophthalmology guidance for any plan to change glaucoma therapy.
Luo N, Jiang X, Hao M et al.. Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials. Frontiers in medicine. 2022
Lee JW, Ahn HS, Chang J et al.. Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. Korean journal of ophthalmology : KJO. 2022
Li J, Lin X, Yu M. Meta-analysis of randomized controlled trials comparing latanoprost with other glaucoma medications in chronic angle-closure glaucoma. European journal of ophthalmology. 2015
Li SM, Chen R, Li Y et al.. Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma. PloS one. 2014
Kandarakis S, Papadopoulos AP, Roussopoulos G et al.. COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Expert opinion on drug safety. 2024
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Latanoprost in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack